Covid 19
COVID-19 early treatment: real-time analysis of 2,466 studies
Excellent resource for finding out about the different possible interventions for Covid and their relative merits
Excellent resource for finding out about the different possible interventions for Covid and their relative merits
How safe are the Covid 19 vaccinations? Real data on the pharmacovigilance databases:
Covid-19 Vaccine Pharmacovigilance Report
(Spoiler alert: Safety signals indicate significant concerns over all of the monitoring databases that exist currently.)
Covid-19 Vaccine Pharmacovigilance Report
(Spoiler alert: Safety signals indicate significant concerns over all of the monitoring databases that exist currently.)
New Zealand shooting victim included in official Covid-19 death stats
Yep, that's right, died from a bullet wound but government helps to pad out the Covid death stats with his demise because he tested positive for Covid-19
Yep, that's right, died from a bullet wound but government helps to pad out the Covid death stats with his demise because he tested positive for Covid-19
Long Covid - is there such a thing?
An article by Sebastian Rushworth MD exploring the Long Covid phenomenon
An article by Sebastian Rushworth MD exploring the Long Covid phenomenon
|
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Background Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities. Prophylaxis combined with the known safety profile of ivermectin Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates. Prospective, July 2020 and December 2020 Inviting the entire population of Itajaí to a medical visit to enroll in the program, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. Study analysis consisted of comparing ivermectin users with non-users using cohorts Results 223,128 citizens of Itajaí considered 159,561 included in the analysis 113,845 (71.3%) regular ivermectin users 45,716 (23.3%) non-users Of these 4,311 ivermectin users were infected, (3.7% infection rate) 3,034 non-users (6.6% infection rate) A 44% reduction in COVID-19 infection rate Risk ratio (RR), 0.56 The regular use of ivermectin led to a 68% reduction in COVID-19 mortality Deaths 25 (0.8%) deaths in the ivermectin group 79 (2.6%) among ivermectin non-users RR, 0.32 p less than 0.0001 When adjusted for residual variables, reduction in mortality rate was 70% There was a 56% reduction in hospitalization rate 44 in the ivermectin group 99 in non ivermectin users After adjustment for residual variables, reduction in hospitalization rate was 67% p less than 0.0001 Conclusion In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates. |
Ivermectin for COVID-19: real-time meta analysis of 67 studies
"Ivermectin is an effective treatment for COVID-19. Treatment is more effective when used early. Meta analysis using the most serious outcome reported shows 66% [53‑76%] and 85% [75‑91%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (which excludes all of the GMK/BBC team studies), with primary outcomes, and after restriction to peer-reviewed studies or Randomized Controlled Trials. Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain statistically significant after exclusions. 45 studies show statistically significant improvements in isolation (35 for primary outcomes, and 32 for the most serious outcome). Results are very robust — in worst case exclusion sensitivity analysis 56 of 67 studies must be excluded to avoid finding statistically significant efficacy."
"Ivermectin is an effective treatment for COVID-19. Treatment is more effective when used early. Meta analysis using the most serious outcome reported shows 66% [53‑76%] and 85% [75‑91%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (which excludes all of the GMK/BBC team studies), with primary outcomes, and after restriction to peer-reviewed studies or Randomized Controlled Trials. Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain statistically significant after exclusions. 45 studies show statistically significant improvements in isolation (35 for primary outcomes, and 32 for the most serious outcome). Results are very robust — in worst case exclusion sensitivity analysis 56 of 67 studies must be excluded to avoid finding statistically significant efficacy."
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
India's Ivermectin Blackout - Part III: The Lesson of Kerala
The New York Times reported India’s colossal drop in COVID cases was unexplainable, while the BBC declared that Kerala’s rise was also a mystery. While new cases of COVID in Uttar Pradesh are rare as million-dollar lottery tickets, in Kerala, a tiny state located in southern India, new daily cases are the same as the United States, nearly one case per thousand. Yet, as we have seen in this series, there has been a curious media blackout on India’s overall success against COVID.
The New York Times reported India’s colossal drop in COVID cases was unexplainable, while the BBC declared that Kerala’s rise was also a mystery. While new cases of COVID in Uttar Pradesh are rare as million-dollar lottery tickets, in Kerala, a tiny state located in southern India, new daily cases are the same as the United States, nearly one case per thousand. Yet, as we have seen in this series, there has been a curious media blackout on India’s overall success against COVID.
Mask mandate and use efficacy for COVID-19 containment in US States
We did not observe association between mask mandates or use and reduced COVID-19 spread in US states. COVID-19 mitigation requires further research and use of existing efficacious strategies, most notably vaccination.
We did not observe association between mask mandates or use and reduced COVID-19 spread in US states. COVID-19 mitigation requires further research and use of existing efficacious strategies, most notably vaccination.
Machine learning and knowledge engineering uncovers significant role of elevated blood glucose in severe Covid-19
Key findings
Key findings
- Elevated BG impairs the ‘first responders’ of our lungs’ immune defense, making the ideal conditions for SARS-CoV-2 to spread.
- Elevated BG causes dysregulations in the immune response that facilitates the cytokine storm and acute respiratory distress syndrome (ARDS).
- Complications caused by Covid-19 – such as hyperinflammation and pro-coagulation – were brought on by elevated BG levels.
- Elevated BG works synergistically with SARS-CoV-2-dependent inactivation of ACE 2 to escalate the disease to multi-organ failure and thrombotic events.
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Conclusions This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant.
Conclusions This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant.
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to eight months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to eight months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.
Natural immunity vs Covid-19 vaccine-induced immunity – Marc Girardot of PANDA
There is ample evidence that vaccinating people recovered from COVID doesn’t bring any benefit. It quite possibly does the opposite, because of the risk of building tolerance to elements of the virus translating into reduced immune potency.
There is ample evidence that vaccinating people recovered from COVID doesn’t bring any benefit. It quite possibly does the opposite, because of the risk of building tolerance to elements of the virus translating into reduced immune potency.
91 Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted
This follow-up chart is the most updated and comprehensive library list of 91 of the highest-quality, complete, most robust scientific studies and evidence reports/position statements on natural immunity as compared to the COVID-19 vaccine-induced immunity and allow you to draw your own conclusion.
This follow-up chart is the most updated and comprehensive library list of 91 of the highest-quality, complete, most robust scientific studies and evidence reports/position statements on natural immunity as compared to the COVID-19 vaccine-induced immunity and allow you to draw your own conclusion.
Covid-19 Vaccine Mandates Are Now Pointless
|
![]()
|